Qiagen NV
QGEN48.560USD
+1.340+2.84%
Close 11/25, 16:00（ET）Quotes delayed by 15 min
10.53BMarket Cap
25.98P/E TTM
More Details of Qiagen NV Company
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Qiagen NV Info
Ticker SymbolQGEN
Company nameQiagen NV
IPO dateSep 01, 1996
CEOMr. Thierry Bernard
Number of employees5765
Security typeOrdinary Share
Fiscal year-endSep 01
AddressHulsterweg 82
CityVENLO
Stock exchangeNYSE Consolidated
CountryNetherlands
Postal code5912 PL
Phone31773556600
Websitehttps://www.qiagen.com/
Ticker SymbolQGEN
IPO dateSep 01, 1996
CEOMr. Thierry Bernard
Company Executives of Qiagen NV
Name
Name/Position
Position
Shareholding
Change
Mr. Roland Sackers
Mr. Roland Sackers
Managing Director, Chief Financial Officer, Member of the Executive Board
Managing Director, Chief Financial Officer, Member of the Executive Board
383.09K
+59.93%
Mr. Thierry Bernard
Mr. Thierry Bernard
Chief Executive Officer, Managing Director, Member of the Executive Board
Chief Executive Officer, Managing Director, Member of the Executive Board
312.13K
+75.76%
Dr. Metin Colpan, Ph.D.
Dr. Metin Colpan, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
171.79K
-57.00%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
47.22K
+10.37%
Prof. Dr. Ross L. Levine, M.D.
Prof. Dr. Ross L. Levine, M.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
16.27K
+30.83%
Prof. Dr. Elaine R. Mardis, Ph.D.
Prof. Dr. Elaine R. Mardis, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
3.97K
--
Mr. Stephen H. (Steve) Rusckowski
Mr. Stephen H. (Steve) Rusckowski
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
24.00
--
Ms. Eva van Pelt
Ms. Eva van Pelt
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Toralf Haag, Ph.D.
Dr. Toralf Haag, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mr. Bert van Meurs
Mr. Bert van Meurs
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Roland Sackers
Mr. Roland Sackers
Managing Director, Chief Financial Officer, Member of the Executive Board
Managing Director, Chief Financial Officer, Member of the Executive Board
383.09K
+59.93%
Mr. Thierry Bernard
Mr. Thierry Bernard
Chief Executive Officer, Managing Director, Member of the Executive Board
Chief Executive Officer, Managing Director, Member of the Executive Board
312.13K
+75.76%
Dr. Metin Colpan, Ph.D.
Dr. Metin Colpan, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
171.79K
-57.00%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
47.22K
+10.37%
Prof. Dr. Ross L. Levine, M.D.
Prof. Dr. Ross L. Levine, M.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
16.27K
+30.83%
Prof. Dr. Elaine R. Mardis, Ph.D.
Prof. Dr. Elaine R. Mardis, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
3.97K
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
By BusinessUSD
Name
Revenue
Proportion
Consumables and Related Revenues
476.33M
89.28%
Instrumentation
57.21M
10.72%
By RegionUSD
Name
Revenue
Proportion
United States
260.49M
48.82%
Europe & Middle East & Africa
179.30M
33.61%
Asia, Pacific & Rest of the World
73.46M
13.77%
Other Americas
20.29M
3.80%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Consumables and Related Revenues
476.33M
89.28%
Instrumentation
57.21M
10.72%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Wellington Management Company, LLP
10.76%
MFS Investment Management
10.56%
The Vanguard Group, Inc.
4.30%
T. Rowe Price International Ltd
3.47%
DWS Investment GmbH
2.13%
Other
68.78%
Shareholders
Shareholders
Proportion
Wellington Management Company, LLP
10.76%
MFS Investment Management
10.56%
The Vanguard Group, Inc.
4.30%
T. Rowe Price International Ltd
3.47%
DWS Investment GmbH
2.13%
Other
68.78%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
48.71%
Investment Advisor
25.43%
Research Firm
5.08%
Pension Fund
1.63%
Sovereign Wealth Fund
1.60%
Hedge Fund
1.10%
Bank and Trust
1.09%
Individual Investor
0.44%
Insurance Company
0.05%
Other
14.86%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
996
177.81M
82.00%
-32.33M
2025Q2
996
189.55M
87.53%
+6.64M
2025Q1
1017
179.03M
82.67%
+27.58M
2024Q4
1010
129.03M
59.70%
-70.06M
2024Q3
1010
183.22M
84.72%
-23.62M
2024Q2
1002
184.34M
84.75%
+8.40M
2024Q1
988
165.20M
76.61%
-7.18M
2023Q4
993
165.11M
76.72%
-10.52M
2023Q3
987
159.93M
74.32%
-12.21M
2023Q2
996
162.43M
75.49%
-6.05M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Wellington Management Company, LLP
26.02M
12%
+1.59M
+6.49%
Jun 30, 2025
MFS Investment Management
23.48M
10.83%
-787.04K
-3.24%
Jun 30, 2025
The Vanguard Group, Inc.
9.16M
4.22%
+372.54K
+4.24%
Jun 30, 2025
T. Rowe Price International Ltd
5.94M
2.74%
+1.79M
+43.10%
Jun 30, 2025
DWS Investment GmbH
3.30M
1.52%
+2.74M
+482.72%
Jun 30, 2025
EARNEST Partners, LLC
4.20M
1.94%
+395.58K
+10.39%
Jun 30, 2025
Amundi Asset Management, SAS
3.98M
1.83%
-217.72K
-5.19%
Jun 30, 2025
Boston Partners
2.36M
1.09%
+13.48K
+0.58%
Aug 31, 2025
BlackRock Institutional Trust Company, N.A.
20.54M
9.47%
+174.28K
+0.86%
Sep 10, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
First Trust Nasdaq Lux Digi Health Solutions ETF
3.85%
Global X Genomics & Biotechnology ETF
3.76%
Invesco Biotechnology & Genome ETF
2.45%
VanEck Biotech ETF
1.81%
ROBO Global Healthcare Technology & Innovation ETF
1.46%
Pacer US Large Cap Cash Cows Growth Leaders ETF
1.18%
Franklin Genomic Advancements ETF
1%
iShares Health Innovation Active ETF
0.93%
Burney US Factor Rotation ETF
0.75%
WisdomTree International Multifactor Fund
0.68%
View more
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion3.85%
Global X Genomics & Biotechnology ETF
Proportion3.76%
Invesco Biotechnology & Genome ETF
Proportion2.45%
VanEck Biotech ETF
Proportion1.81%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.46%
Pacer US Large Cap Cash Cows Growth Leaders ETF
Proportion1.18%
Franklin Genomic Advancements ETF
Proportion1%
iShares Health Innovation Active ETF
Proportion0.93%
Burney US Factor Rotation ETF
Proportion0.75%
WisdomTree International Multifactor Fund
Proportion0.68%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 18, 2024
Merger
25→24.25
Jan 18, 2024
Merger
25→24.25
Date
Type
Ratio
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 18, 2024
Merger
25→24.25
Jan 18, 2024
Merger
25→24.25
Jan 18, 2024
Merger
25→24.25
Jan 18, 2024
Merger
25→24.25
FAQs
Who are the top five shareholders of Qiagen NV?
The top five shareholders of Qiagen NV are:
Wellington Management Company, LLP holds 26.02M shares, accounting for 12.00% of the total shares.
MFS Investment Management holds 23.48M shares, accounting for 10.83% of the total shares.
The Vanguard Group, Inc. holds 9.16M shares, accounting for 4.22% of the total shares.
T. Rowe Price International Ltd holds 5.94M shares, accounting for 2.74% of the total shares.
DWS Investment GmbH holds 3.30M shares, accounting for 1.52% of the total shares.
Wellington Management Company, LLP holds 26.02M shares, accounting for 12.00% of the total shares.
MFS Investment Management holds 23.48M shares, accounting for 10.83% of the total shares.
The Vanguard Group, Inc. holds 9.16M shares, accounting for 4.22% of the total shares.
T. Rowe Price International Ltd holds 5.94M shares, accounting for 2.74% of the total shares.
DWS Investment GmbH holds 3.30M shares, accounting for 1.52% of the total shares.
What are the top three shareholder types of Qiagen NV?
The top three shareholder types of Qiagen NV are:
Wellington Management Company, LLP
MFS Investment Management
The Vanguard Group, Inc.
Wellington Management Company, LLP
MFS Investment Management
The Vanguard Group, Inc.
How many institutions hold shares of Qiagen NV (QGEN)?
As of 2025Q3, 996 institutions hold shares of Qiagen NV, with a combined market value of approximately 177.81M, accounting for 82.00% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -5.53%.
What is the biggest source of revenue for Qiagen NV?
In FY2025Q2, the Consumables and Related Revenues business generated the highest revenue for Qiagen NV, amounting to 476.33M and accounting for 89.28% of total revenue.
